Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

Izzo, A. A.; Camilleri, M.
August 2008
Gut;Aug2008, Vol. 57 Issue 8, p1140
Academic Journal
A multitude of physiological effects and putative pathophysiological roles have been proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and pancreas. These range from effects on epithelial growth and regeneration, immune function, motor function, appetite control, fibrogenesis and secretion. Cannabinoids have the potential for therapeutic application in gut and liver diseases. Two exciting therapeutic applications in the area of reversing hepatic fibrosis as well as antineoplastic effects may have a significant impact in these diseases. This review critically appraises the experimental and clinical evidence sup- porting the clinical application of cannabinoid receptor-based drugs in gastrointestinal, liver and pancreatic diseases. Application of modern pharmacological principles will most probably expand the selective modulation of the cannabinoid system peripherally in humans. We anticipate that, in addition to the approval in several countries of the CB1 antagonist, rimonabant, for the treatment of obesity and associated metabolic dysfunctions, other cannabinoid modulators are likely to have an impact on human disease in the future, including hepatic fibrosis and neoplasia.


Related Articles

  • Porphyria Cutanea Tarda in Association with Hemosiderosis of the Liver. Strickland Jr., G. Thomas // American Journal of Gastroenterology;Sep1968, Vol. 50 Issue 3, p202 

    A 43-year old Caucasian woman with symptoms and physical findings of porphyria cutanea tarda was noted to have increased uro- and coproporphyrins in the urine and liver tissue which fluoresced with ultraviolet light. She had an elevated serum iron with excessive saturation of...

  • Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Rake, Peter; Visser, Gepke; Labrune, Philippe; Leonard, James V.; Ullrich, Kurt; Smit, Peter A. // European Journal of Pediatrics. Supplement;2002, Vol. 161, pS20 

    Glycogen storage disease type I (GSD I) is a relatively rare metabolic disease and therefore, no metabolic centre has experience of large numbers of patients. To document outcome, to develop guidelines about (longterm) management and follow-up, and to develop therapeutic strategies, the...

  • Dyslipidcmia drugs used in Pediatrics. Unitary dose. Guzmán, David Calderón; García, Ernestina Hernández; Mejía, Gerardo Barragán // Revista Mexicana de Pediatria;mar/abr2012, Vol. 79 Issue 2, p109 

    Pharmacological treatment of dyslipidemia in children is an option for reducing the prevalence of this metabolic disease, it is therefore necessary to expand the research studies on this type of drugs in children affected with this disease: because the medi-cines available have been developed...

  • Erratum. Bentham Science Publishers // Endocrine, Metabolic & Immune Disorders - Drug Targets;Mar2010, Vol. 10 Issue 1, p83 

    It has come to our notice that the article published in Current Drug Targets-Immune Endocrine and Metabolic Disorders, Volume 4, Issue 1, page numbers 75-78, is largely the same as that published in the Journal Biochemical Pharmacology. The publishers have therefore decided to retract the...

  • Current Pharmacological Treatment of Nonalcoholic Fatty Liver. Portincasa, Piero; Grattagliano, Ignazio; Palmieri, Vincenzo O.; Palasciano, Giuseppe // Current Medicinal Chemistry;2006, Vol. 13 Issue 24, p2889 

    Nonalcoholic fatty liver disease (NAFLD) is a frequent and potentially progressive chronic liver disease that occurs in subjects who do not abuse alcohol. NAFLD is often associated with obesity, metabolic syndrome and insulin resistance and its more aggressive form, nonalcoholic steatohepatitis...

  • Providing Practitioners with Information and Tools.  // Pharmacy Today;Mar2004, Vol. 10 Issue 3, p1 

    Updates on the provision of a comprehensive array of information and tools from the nation's leading clinical pharmacist researchers to support advanced patient care services in the area of metabolic syndrome. Organization of the APhA Foundation's 2003 National Clinical Issues Forum: Metabolic...

  • A New Perspective of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral CB1R Blockers without Crossing the Blood-Brain Barrier. Yen-Ku Wu; Ching-Fang Yeh; Tai Wei Ly; Ming-Shiu Hung // Current Topics in Medicinal Chemistry;Jun2011, Vol. 11 Issue 12, p1421 

    Since Rimonabant was withdrawn in Europe in 2008 because of its substantial CNS risk factors including depression and anxiety, the development of anti-obesity drugs targeting CB1R in the brain has been suspended and/or terminated globally. Instead, developing peripherally restricted CB1R...

  • Molecular Biology of the Enzymes that Degrade Endocannabinoids. Puffenbarger, Robyn A. // Current Drug Targets - CNS & Neurological Disorders;Dec2005, Vol. 4 Issue 6, p625 

    Endocannabinoid circuits have been shown to regulate a number of important pathways including pain, feeding, memory and motor coordination. Direct manipulation of endocannabinoid tone, therefore, may relieve disease symptoms related to analgesia, obesity, Alzheimer's and Parkinson's in humans....

  • G1359A polimorfismo del receptor CB1 endocanabinoide (CNR1) en parámetros antropométricos y riesgo cardiovascular en pacientes con obesidad mórbida. de Luis, D. A.; Sagrado, M. González; Aller, R.; Izaola, O.; Conde, R.; Castrillón, J. L. Pérez; Romero, E. // Nutricion Hospitalaria;nov/dic2009, Vol. 24 Issue 6, p688 

    Background: A polymorphism (1359 GIA) of the CB1 gene has been described, it was reported as a common polymorphism in European populations. The aim of our study was to investigate the influence of this polymorphism of CB1 receptor gene on obesity anthropometric parameters, cardiovascular risk...


Read the Article


Sign out of this library

Other Topics